Monitoring illicit psychostimulants and related health issues
Brunt, T.M.

Citation for published version (APA):
References


177
(BZP-party pills) amongst young people in New Zealand. *Harm Reduct. J.* 4, 18


Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA. (2002). The content of ecstasy tablets: implications for the study of their long-term effects. *Addiction* 97, 1531-1536


on snorting, smoking, swallowing and injecting. *Addiction* 103(7), 1174-1186


Docherty JR, Green AR. (2010). The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine


Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM,


Henderson, LA, Glass, WJ. (1994). *LSD: Still with Us after All These Years.* Wiley & Sons, John Incorporated, San Fransisco, CA


Jaehne EJ, Salem A, Irvine RJ. Pharmacological and behavioral derterminants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia. Psychopharmacology (Berl) 194(1), 41-52


determining pill content and purity: Implications for policy and practice. *Int. J. Drug Policy* 17, 464-472


Legleye S, Ben Lakhdar C, Spilka S. (2008). Two ways of estimating the euro value of the illicit market for cannabis in France. Drug Alcohol Rev. 27(5), 466-472


McCann UD, Ridenour A, Shaham Y, Ricaurte GA. (1994). Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10(2), 129-138


McCann UD, Eligulashvili V, Ricaurte GA. (2000). (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42(1), 11-16


Miksys S., Tyndale R.F. (2004). The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab. Rev. 36, 313-33


Parrott AC. (2004a). MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. *Neuropsychobiology* 50(4), 329-335


Parrott AC. (2006). MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. *J. Psychopharmacology* 20, 147-163


Staack RF, Maurer HH. (2003). Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone. *J. Anal. Toxicol.* 27, 560-568


Tancer M, Johanson CE. (2003). Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. *Drug Alcohol Dependence* 72, 33-44

Tanner-Smith EE. (2006). Pharmacological content of tablets sold as "ecstasy": results from an online testing service. *Drug Alcohol Dependence* 83, 247-254


Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. (2007). A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). *Neuroscience* 146(2), 509-514


United States Drug Enforcement Administration. (2010). *Cocaine*. http://www.justice.gov/ndic/pubs31/31379/cocaine.htm#Figure3


202


